A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma
Clinical trial NCT07229417 · RECRUITING
Trial details
- NCT number
- NCT07229417
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-22
- Primary completion
- 2027-09-30
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.